EnWave Corporation
TSX VENTURE : ENW
FRANKFURT : E4U

EnWave Corporation

October 27, 2009 09:30 ET

EnWave to Test Animal Vaccines with Saskatchewan Research Council Using freezeREV Pharmaceutical Dehydration Technology

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 27, 2009) - EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4W) ("EnWave," or "the Company"), has signed an agreement with the Saskatchewan Research Council (SRC) to install the Company's freezeREV in-vial pharmaceutical dehydration technology for animal vaccine testing at the SRC Fermentation Pilot Plant in Saskatoon, Saskatchewan. SRC scientists will conduct a series of viability and shelf-life tests using two proprietary Escherichia coli ("E.coli") vaccines for swine to determine the potential benefits of EnWave's dehydration technology over the current preservation method, freeze drying.

Following the testing of SRC's E.coli vaccines, SRC will make their facilities available to third-party producers of vaccines to conduct their own testing of EnWave's freezeREV technology on a fee-for-service basis. SRC will also use their extensive industry expertise to evaluate the current freezeREV prototype and provide input into EnWave's current design concepts for the next generation multi-vial prototype.

EnWave's proprietary Radiant Energy Vacuum ("REV") technology combines microwave energy with vacuum pressure to produce high-speed dehydration of live or active pharmaceuticals in vials. The Company has developed two versions of REV for use in drying live or active pharmaceuticals: bioREV(TM), a dehydration method for materials which require a gentler drying process without extreme temperature changes or freezing, and freezeREV, a dehydration method for frozen material where low moisture levels in the final product are imperative for long product shelf-life.

"The Saskatchewan Research Council currently performs pilot-scale vaccine production for a number of vaccine producers in Canada, and they are keen to find a dehydration alternative that is faster and less expensive than freeze drying," said Dr. Tim Durance, EnWave's Chairman & Co-CEO. "Our prototype freezeREV technology is designed to dry material in minutes, compared to days required for conventional freeze dryers. It will significantly reduce processing costs.

While the technology worked well for recent samples of antibodies, we are looking forward to testing the machine on a new vaccine in order to further prove the concept of freezeREV. Additionally, we are saving the company many hundreds of thousands of dollars by eliminating the need to build a laboratory, capable of handling pathogenic material, and instantly acquiring access to the highly-trained scientists and engineers at the SRC."

"SRC is dedicated to providing research, development and demonstration solutions that address current industry needs," said Dale Kelly, vice-president of SRC's Agriculture, Biotechnology and Food Division. "We are excited to work with EnWave on piloting Radiant Energy Vacuum technology to evaluate its potential as an alternative to current processing and preservation methods of freeze drying for vaccines and biologics."

About SRC

SRC is Saskatchewan's leading provider of applied R&D and technology commercialization. It takes the leading-edge knowledge developed in Saskatchewan and sells it to the world and, at the same time, brings the best knowledge the world has to offer and applies it to the unique Saskatchewan situations.

SRC was established in 1947 to advance the development of the province in the physical sciences. Today, the company has evolved to become a market-driven corporation, selling services and products to companies in Saskatchewan and around the world. The corporation has more than 340 staff. Annual revenues are about $41 million and growing. More information is available about the SRC at http://www.src.sk.ca/.

About EnWave

Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is focused on the development of new methods of dehydrating food and biological materials using Radiant Energy Vacuum technology under its nutraREVTM, powderREV, bioREVTM and freezeREV brands. REV technology combines microwave energy transfer under vacuum to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include fruit, vegetables, probiotics, enzymes, proteins, food cultures, vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation

Dr. Tim Durance, Chairman & Co-CEO

This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company's REV technology can or will improve dehydration processes in the target industries; even if the Company's REV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company's REV technology.

The TSX Venture Exchange has neither approved nor disapproved the information contained herein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information